NURS 3210 ALG 4

To prevent overlap or disruption of action potentials

Heart problems, high blood pressure, electrolyte imbalance, certain medications, heavy drinking, thyroid disease, obstructive sleep apnea, and strong emotional stress.

Slowing the heart rate and reducing the frequency of abnormal beats.

Pulmonary toxicity

To convert the rhythm to a normal sinus rhythm

Monitoring vital signs and cardiac rhythm

Class II (beta blockers)

Increasing the refractory period of cardiac cells

Hypotension and bradycardia

Initiate CPR

Calcium channel blocker

Pulmonary toxicity

Anti-dysrhythmic medications such as amiodarone

Vital signs, ECG, and cardiac enzyme levels

They slow the heart rate and reduce AV node conduction

Cardiac rhythm and vital signs

Lidocaine and phenytoin

Pulmonary toxicity, thyroid disorders, bradycardia, hypotension, SA node dysfunction, etc.

Amiodarone's long half-life means that therapeutic and adverse effects can persist for months after discontinuation.

Supreventricular Tachycardia

Rapid onset and short duration

Heart rate, blood pressure, heart rhythms, general well-being, skin color, temperature, and heart and breath sounds

Allows for fast circulation to the cardiac tissue

It may take 2 to 3 months for adverse effects to subside after discontinuation

Anti-anginals dilate the blood vessels, particularly the coronary arteries, increasing blood flow into the heart muscle, which is crucial for patients with angina.

Assess vital signs and distress level, verify dosage, route, and assist with sublingual administration, and follow up with medical evaluation.

Medication adherence and lifestyle management are crucial in managing angina, as they help reduce the frequency and severity of angina episodes.

It is critical for nurses to assess the vital signs of the patient receiving antianginal therapy, particularly blood pressure and heart rate, due to the risk of hypotension and bradycardia.

The primary goal of pharmacologic management of ventricular tachycardia is to convert the dysrhythmia to a normal sinus rhythm or slow the ventricular rate.

The classification of antidysrhythmic drugs that slow the heart rate and reduce the frequency of abnormal beats is Class II antidysrhythmics.

A potential adverse effect of amiodarone therapy is pulmonary toxicity.

The nurse should assess for signs of toxicity, such as bradycardia, QT interval prolongation, and torsades de pointes.

Bleeding, blood in urine/stool, petechiae, nosebleeds, and increased bleeding from menstrual cycle.

Rivaroxaban is a direct oral anticoagulant that does not require frequent monitoring of blood and dosage adjustment, whereas warfarin requires frequent monitoring, and enoxaparin is administered through painful and inconvenient injections.

Double-checking the physician's order, dosage, rate of infusion, bolus dosage, and bolus concentration; properly configuring and programming the infusion smart pump; monitoring aPTT levels; frequent assessment for bleeding; and patient education.

aPTT levels within the therapeutic range (1.5 to 2.5 times the normal control value), and absence of bleeding or signs of bleeding.

To convert the ventricular tachycardia to a normal sinus rhythm and prevent further complications.

Monitoring for signs of bleeding, such as petechiae, nosebleeds, and increased bleeding from menstrual cycle.

Class II antidysrhythmic drugs, such as beta blockers.

Slowing the heart rate and reducing the frequency of abnormal beats by blocking the influx of calcium ions into the cardiac cells.